Oligonucleotide array CGH studies in myeloproliferative neoplasms: Comparison with JAK2V617F mutational status and conventional chromosome analysis

Leukemia Research

Volumn 33, Issue 5, 2009, Pages 662-664

  Tefferi, Ayalew ^a   Sirhan, Shireen ^a   Sun, Yi ^b   Lasho, Terra ^a   Finke, Christy M ^a   Weisberger, James ^b,c   Bale, Sherri ^d   Compton, John ^d   LeDuc, Charles A ^e   Pardanani, Animesh ^a   Thorland, Erik C ^a   Shevchenko, Yuriy ^d   Grodman, Marc ^b,e   Chung, Wendy K ^e  

^a MAYO CLINIC   (United States)

^b Bioreference Laboratory   (United States)

^c GenPath BioReference Laboratories   (United States)

^d GENEDX   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Array CGH; JAK2 V617F; Myelofibrosis; Myeloproliferative; Polycythemia; Thrombocythemia

Indexed keywords

BCR ABL PROTEIN; OLIGONUCLEOTIDE;

ADULT; AGED; ARTICLE; CHROMOSOME ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CYTOGENETICS; DNA MICROARRAY; FEMALE; GENE MUTATION; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MYELOID METAPLASIA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; THROMBOCYTHEMIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; FEMALE; HUMANS; JANUS KINASE 2; KARYOTYPING; MALE; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDERS; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 61449167048     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.09.009     Document Type: Article

References (22)

1. Haferlach C., Rieder H., Lillington D.M., et al. Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes. Genes Chromosomes Cancer 46 (2007) 494-499
2. Frohling S., Schlenk R.F., Kayser S., et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood 108 (2006) 3280-3288
3. Haase D., Germing U., Schanz J., Pfeilstocker M., Nosslinger T., Hildebrandt B., et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 110 (2007) 4385-4395
4. Bacher U., Haferlach T., Kern W., Hiddemann W., Schnittger S., and Schoch C. Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information. Ann Hematol 84 (2005) 250-257
5. Tefferi A., and Vardiman J.W. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22 (2008) 14-22
6. Tefferi A., and Gilliland D.G. Oncogenes in myeloproliferative disorders. Cell Cycle 6 (2007) 550-566
7. Steensma D.P., and Tefferi A. Cytogenetic and molecular genetic aspects of essential thrombocythemia. Acta Haematol 108 (2002) 55-65
8. Gangat N., Strand J., Lasho T.L., Finke C.M., Knudson R.A., Pardanani A., et al. Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates. Eur J Haematol 80 (2008) 197-200
9. Tefferi A., Mesa R.A., Schroeder G., Hanson C.A., Li C.Y., and Dewald G.W. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol. 113 (2001) 763-771
10. Tefferi A., Dingli D., Li C.Y., and Dewald G.W. Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia. Cancer 104 (2005) 1656-1660
11. Dupriez B., Morel P., Demory J.L., et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 88 (1996) 1013-1018
12. Reilly J.T., Snowden J.A., Spearing R.L., et al. Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Br J Haematol 98 (1997) 96-102
13. Smeets D.F. Historical prospective of human cytogenetics: from microscope to microarray. Clin Biochem. 37 (2004) 439-446
14. Coe B.P., Ylstra B., Carvalho B., Meijer G.A., Macaulay C., and Lam W.L. Resolving the resolution of array CGH. Genomics 89 (2007) 647-653
15. Tefferi A., Thiele J., Orazi A., et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110 (2007) 1092-1097
16. Tefferi A., and Pardanani A. Mutation screening for JAK2V617F: when to order the test and how to interpret the results. Leuk Res 30 (2006) 739-744
17. Pardanani A., Hood J., Lasho T., et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 21 (2007) 1658-1668
18. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 22 (2008) 23-30
19. Mohamedali A., Gaken J., Twine N.A., et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 110 (2007) 3365-3373
20. Plo I., Nakadake M., Wiesmuller L., Giraudier S., Villeval J.L., and Vainchenker W. JAK2 activation stimulates homologous recombination and genetic instability. Blood 110 (2007) 207a, Abstract# 67
21. Gondek L.P., Dunbar A.J., Szpurka H., McDevitt M.A., and Maciejewski J.P. SNP array karyotyping allows for the detection of uniparental disomy and cryptic chromosomal abnormalities in MDS/MPD-U and MPD. PLOS ONE 2 (2007) e1225
22. Evers C., Beier M., Poelitz A., et al. Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH. Genes Chromosomes Cancer 46 (2007) 1119-1128